Aptamers could inhibit the virus at the stage of viral entry by blocking the interactions between the viral envelope glycoprotein and the cellular receptor.8 Our previous work reported a DNA aptamer ZE2 could block HCV E2 from binding the CD81 receptor and the infection to human hepatocytes. This evidence concerns the gene ERVW-1 and infection.